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Abstract
Background: Recent studies have shown that androgen displays an inhibitory effect on breast cancer cell lines that express androgen recep-
tor (AR) but not estrogen receptor (ER) and progesterone receptor (PR). We have previously reported that approximately 1/3 of ER negative 
high grade invasive ductal carcinomas express AR. Thus, AR can serve as a potential therapeutic target for this group of patients.
Aim: Here we investigated AR expression patterns in 980 consecutive breast carcinomas. 
Results: We found that (1) AR was expressed more frequently (77%) than ER (61%) and PR (60%) in breast carcinomas; (2) AR 
expression was associated with ER and PR expression (P , 0.0001), small tumor size (P = 0.0324) and lower Ki-67 expression 
(P = 0.0013); (3) AR expression was found in 65% of ER negative tumors; (4) AR expression was associated with PR and Ki-67 in 
ER negative tumors, but not in ER positive tumors; (5) AR expression was higher in ER positive subtypes (Luminal A, Luminal B and 
Luminal HER2 subtypes, 80%–86%) and lower in ER negative subtypes [HER2, triple negative (TN), and TN EFGR positive subtypes; 
52%–66%], with over 50% of TN tumors expressing AR. 
Conclusion: More breast carcinomas express AR than ER and PR, including significant numbers of ER negative and TN tumors, for 
which AR could serve as a potential therapeutic target.
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Introduction
Breast cancer is one of the most common malignancies 
in women worldwide and the second most common 
cause of cancer-related death in women. Currently, 
breast cancer is treated by multi-modality therapies 
based  on  the  pathologic  characteristic  of  each 
tumor.1,2  Targeting  therapies  to  estrogen  receptor 
(ER)  and  HER2  in  breast  carcinoma  have  shown 
remarkable  clinical  efficacy  for  the  appropriate 
subsets of patients.3,4 However, only about 15% and 
70%  of  breast  cancers  are  positive  for  HER2  and 
ER, respectively; and about 15% of the tumors are 
ER, progesterone receptor (PR) and HER2 negative 
[Triple  Negative  (TN)  tumors],5,6  which  will  not 
benefit from these targeted therapies.
The role of the androgen receptor (AR) in breast 
carcinomas  has  drawn  great  attention  in  recent 
years, especially due to its expression in ER and PR 
  negative  breast  carcinomas.7,8  We  have  previously 
reported that approximately 1/3 of ER negative high 
grade invasive ductal carcinomas express AR.9 Breast 
cancer with BRCA1/2 mutants also shows a similar 
rate of AR expression.10 AR expression also corre-
lates with   better prognosis for both primary and meta-
static breast cancer.11,12 A recent study has shown that 
androgen dehydroepiandrosterone sulfate (DHEAS) 
inhibits the growth of breast cancer cell lines that 
express AR but not ER and PR.13 Thus, AR has been 
suggested to be able to serve as a potential therapeutic 
target for the subgroup of breast carcinomas that are 
AR positive/ER negative.14
Breast cancer is a very heterogeneous group of 
tumors that vary in clinical behavior and response 
to therapy. Gene expression profiling has provided 
the molecular basis for the heterogeneity of breast 
cancer; and also subdivided breast cancer into sev-
eral  clinically  distinct  molecular  subtypes.15–17  ER, 
PR,  HER2,  and  more  recently  Ki-67,  CK5/6  and 
EGFR  have  been  used  by  many  investigators  as 
immunohistochemical (IHC) surrogates for molecular 
classification with comparable results.18–22 Although 
no universally accepted definition for each subtype 
is present at this point, most studies have chosen to 
use definitions proposed by Nielsen,18 Livasy19 and 
Cheang.20 This current study aims to investigate the 
expression patterns of AR in a large cohort of Chinese 
breast cancer patients, with a focus on ER negative 
and TN breast cancer, and breast cancer of different 
molecular subtypes.
Materials and Methods
Patient selection
A total of 980 consecutive cases of invasive breast 
carcinomas between 2004 and 2009 were reviewed 
from the files of the Department of Pathology of the 
First Clinical Hospital of Harbin Medical University 
in China. 89 cases of DCIS were also identified from 
the  same  period  and  excluded  from  the  study. All 
patients underwent surgical excision before receiving 
chemotherapy,  radiotherapy  or  adjuvant  hormonal 
therapy.  Clinicopathological  information  including 
age of patients, tumor size and lymph node status 
were obtained from the files. The histological types 
and grades of the tumors were determined by follow-
ing the WHO classification (2003).23
immunohistochemistry analysis
The study protocol was approved by the Human Ethics 
Review Committee of Harbin Medical University. The 
information for primary antibodies for AR, ER, PR, 
HER2, Ki-67, and EGFR used in the study is listed 
in Table 1. Formalin-fixed, paraffin-embedded tissue 
blocks were cut into 3 micron thick serial sections that 
were mounted on pre-coated slides. The sections were 
de-paraffinized,  rehydrated,  and  rinsed  in  distilled 
water, and then treated with 3% hydrogen peroxide   
Table 1. Sources and dilutions of antibodies.
Antibody poly- vs. monoclonal clone no. Manufacturer Dilution
AR monoclonal AR441 Maixin_Bio, China Working liquid
eR monoclonal eP1 ZSgB-BiO, China Working liquid
PR monoclonal SP2 Maixin_Bio, China Working liquid
Ki-67 monoclonal eP5 ZSgB-BiO, China Working liquid
heR2 monoclonal eP3 ZSgB-BiO, China Working liquid
egFR monoclonal egFR.113 Maixin_Bio, China Working liquid
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solution  for  10  minutes  to  block  endogenous 
peroxi  dases.  Antigen  retrieval  was  achieved  by 
  heating in a water bath with EDTA (pH 9.0; ZLI-9069; 
901022, ZSGB-BIO, China) for AR, or in citrate buffer 
(pH 6.0) for ER, PR, HER2 and Ki67, or pretreated in 
pepsin (ZLI-9013; 572031A, ZSGB-BIO, China) for 
EGFR. The aforementioned   primary antibodies were 
incubated for an hour, and then incubated with the 
secondary, biotinylated antibody for 30 minutes. After 
washing, sections were incubated with streptavidin-
peroxidase  for  40    minutes.  3,3′-diaminobenzidine 
(DAB) was used as   chromogen. Samples were scored 
as positive for ER, PR and AR (Figure 1) when at 
least 10% of nuclei of tumor cells were immunore-
active.  Ki67  expression  was  determined  by  mean 
positive  nuclear  staining  percentage  from  10  high 
power fields; over 14% is considered positive. HER2 
was considered positive when .10% of tumor cells 
with 3+ membranous staining was observed; EGFR 
was considered positive when tumor cells with 1+ or 
greater staining were observed.
IHC-Based definitions for each subtype 
in the molecular classification
A 5 marker panel (ER, PR, HER2, Ki-67, and EGFR) 
was used to determine each subtype of breast cancer. 
The definition and number of breast cancer in each 
subtype for the current study are shown in Table 8.
Statistical analysis
Apart from the descriptive statistics, such as mean 
of  continue  variables  and  percent  for  categorical 
variables, the difference between AR positive and AR 
negative  was  tested  by  using  two-sided    Spearman 
two-sample  test  rank  for  continue  variables  and 
  Fisher’s exact test was used for categorical variables. 
The software SAS 9.2 (Cary, NC, USA) was used in 
the data analysis.
Results
The age of patients ranged from 22 to 94 years old, 
with a mean age of 51 years. Among the 980 cases, 
868  were  infiltrating  ductal  carcinoma  (IDC),  52 
were infiltrating lobular carcinoma (ILC), 19 were 
  medullary carcinoma, 21 were mucinous carcinoma, 
and 20 were rare-types of breast carcinomas including 
squamous cell carcinoma, neuroendocrine carcinoma, 
etc. The rate of AR expression was 77%, and the rates 
for ER, PR and HER2 expression were 61%, 60%, 
17%, respectively. AR expression was highest in ILC 
(87%)  and  lowest  in  medullary  carcinoma  (37%) 
(Table 2); and highest in grade 1 tumors (91%) and 
lowest in grade 3 tumors (57%) (Table 3).
AR expression was significantly associated with 
the  expression  of  ER  and  PR  (P  ,  0.0001),  and 
also inversely related to tumor size (P = 0.0324) and 
Ki-67 expression (P = 0.0013). There were no sig-
nificant associations between the expression of AR 
Figure 1. immunohistochemical stain for AR, 40× of original magnification.
Table 2. expression of AR, eR, PR and heR2 in different types of breast carcinomas.
Type percent of positive expression (%)
AR eR pR
iDCa (868 cases) 77 (668 cases) 62 (538 cases) 59 (512 cases)
iLCb (52 cases) 87 (45 cases) 67 (35 cases) 71 (37 cases)
Medullary (19 cases) 37 (7 cases) 11 (2 cases) 11 (2 cases)
Mucinous (21 cases) 88 (18 cases) 76 (16 cases) 71 (15 cases)
Othersc (20 cases) 60 (12 cases) 60 (12 cases) 85 (17 cases)
Total cases (980) 77 (755 cases) 61 (598 cases) 60 (588 cases)
notes: aIDC, Infiltrating Ductal Carcinoma; bILC, Infiltrating Lobular Carcinoma; cOthers, squamous cell carcinoma, neuroendocrine tumors, etc.
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Table 3. expression of AR, eR, PR and heR2 in different histologic grades of iDC.
Type percent of positive expression (%)
AR eR pR
iDC (868 cases) 77 (668 cases) 62 (538 cases) 59 (512 cases)
  *g1 (55 cases) 91 (50 cases) 82 (45 cases) 84 (46 cases)
  g1-2 (41 cases) 90 (37 cases) 76 (31 cases) 71 (29 cases)
  g2 (669 cases) 76 (509 cases) 62 (415 cases) 59 (395 cases)
  g2-3 (73 cases) 77 (56 cases) 53 (39 cases) 55 (40 cases)
  g3 (30 cases) 57 (17 cases) 30 (9 cases) 23 (7 cases)
note: *g, grade.
Table 5. expression of AR in eR positive and eR negative 
tumors.
AR positive cases Totals cases
eR positive 503 (84%) 597
eR negative 248 (65%) 383
Total 751 (77%) 980
Table  4.  Correlation  between AR  expression  and  age, 
tumor size, Ln stage, and expression of eR, PR, heR2, 
egFR and Ki67.*
rs P value
Age 0.13350 0.6022
Tumor size -0.31765 0.0324
nodal metastasis -0.04456 0.1454
eR expression 0.54546 ,0.0001
PR expression 0.32267 ,0.0001
heR2 over-expression -0.03476 0.7348
egFR expression -0.03090 0.4782
Ki-67 expression -0.31765 0.0013
and the ages of patients, lymph node involvement, or 
expression of HER2 and EGFR (Table 4).
The  rates  of  AR  expression  were  84%  for  ER 
 positive  tumors  and  65%  for  ER  negative  tumors 
(Table  5).  Interestingly,  when  comparing  the 
  expression  of AR  in  ER  positive and  ER negative 
tumors,  AR  expression  was  significantly  associ-
ated with PR expression (P , 0.0001) in ER nega-
tive tumors (Table 7), but not in ER positive tumors 
(Tables  6).  Similar  observations  were  seen  for  the 
mean Ki-67 levels. Other factors including the age of 
patients, tumor size, nodal metastasis, and HER2 and 
EGFR expression were not associated with AR expres-
sion in either ER positive or ER negative tumors.
Among the 980 cases, the distribution of  Luminal A,   
Luminal B, Luminal HER2, HER2 over-expression, 
TN  and  TN  EGFR+  subtypes  were  27%,  24%, 
21%, 12%, 10% and 6%, respectively (Table 8). AR 
expression was higher in three ER positive subtypes 
(Luminal A, Luminal B and luminal HER2 subtypes, 
range: 80%–90%) and lower in three ER negative sub-
types (HER2 over-expression, TN, and TN EFGR+ 
subtypes, range: 52%–66% Table 9). AR expression 
was  significantly  different  between  luminal  HER2 
and HER2 over-expression subtypes (P , 0.0001), 
while  there  was  no  significant  difference  between 
luminal A and B subtypes, luminal B and luminal 
HER2 subtypes, HER2 and TN subtypes, HER2 and 
TN EGFR+ subtypes, and TN and TN EGFR+ sub-
types (Table 10).
Discussion
Like  ER  and  PR,  AR  is  also  a  steroid  hormone 
nuclear protein, but the clinical significance and func-
tional role of AR has not been well defined in breast 
cancer.24,25 Studies have shown that AR expression is 
found in about 70% of breast cancers,26,27 similar to 
the 77% we found with our Chinese patients. A study 
from Poland with 488 cases showed the AR expres-
sion rate was 43%, but their criterion for its positivity 
was not mentioned.28 We confirmed that AR is more 
frequently  expressed  in  our  Chinese  breast  cancer 
patients than ER and PR and its expression is closely 
associated with ER and PR. We observed that 65% 
of ER negative tumors express AR, higher than the 
30% rate from other studies.7,9,11,26,27 One possibility is 
the higher cut off (10%) used in the current study as 
a positive value for ER, PR, and AR, which defined 
more negative cases compared to the current CAP/
ASCO Guideline.29 The higher rates for ER negative 
tumors  (39%)  compared  to  other  studies30,31  may 
also be explained by the higher cut off point used in 
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current study. Another possibility for this difference 
may due to the specificity of the antibodies used in 
the current study.32 Nevertheless, we confirmed that a 
significant portion of ER negative tumors expressed 
AR  in  our  patient  population,  which  provides  this 
subgroup with a potential therapeutic target.
Comparing the relationship between AR expres-
sion and molecular classification, we found that AR 
expression is higher in ER positive subtypes than in 
ER negative subtypes, which is comparable with pre-
vious reports,31,33 though the definitions for each sub-
type were not identical. It is very interesting to see 
the significant difference in AR expression between 
Luminal HER2 and HER2 over-expression subtype. 
Both  subtypes  over-express  HER2,  but  they  are 
different in their expression of ER and/or PR, sug-
gesting the close relation between AR and ER/PR. 
A recent study from Micello et al34 reported a 77% 
AR expression rate in HER2 positive breast carcino-
mas, comparable with what we observed in this study 
(66%–86%). Our prior studies with 17 breast cancer 
cell lines also showed that all 4 ER negative HER2 
positive cell lines expressed AR.35 This is especially 
interesting since an earlier study36 has suggested that 
in breast cancer, the growth inhibitory effect resulting 
from AR activation can counterbalance the growth 
stimulating effect by HER2 over-expression.
We  did  not  observe  an  age  difference  between 
AR  positive  and AR  negative  tumors,  even  when 
we subdivided the tumors into ER positive and ER 
negative groups. Hu et al37 recently reported that in 
postmenopausal patients, AR expression is associated 
with a more favorable prognosis among women with 
ER-positive tumors, but not among patients with ER-
negative tumors. In fact, AR expression is associated 
with increased breast cancer-related mortality in their 
patients who have triple negative breast cancer. AR 
expression is associated with more favorable patho-
logic features including small tumor size (P = 0.0324) 
and lower Ki-67 expression (P = 0.0013) in current 
study, similar to previously reported studies.31
With the high expression rate of AR, especially in 
ER negative or TN breast cancer, investigations of 
AR as a therapeutic target have been the subject of 
extensive research.14,38 Preclinical studies with breast 
cancer cell lines have shown the inhibitory role of 
androgen (such as dehydroepiandrosterone) on ER-/
PR-/AR+ cells.13 It is thought that if androgen were 
used to treat ER-/AR+ tumors, its therapeutic effect 
would be maximized with aromatase inhibitors, since 
Table 7. Clinical-pathological features for AR expression in eR- tumors (383 cases).
AR+ (248) AR- (135) P value
Age (mean years) 50.12 51.23 0.3955
Tumor size (mean cm) 2.09 2.28 0.0956
Positive nodal metastasis (163 cases) 98 (60%) 65 (40%) 0.1062
Positive PR expression (106 cases) 86 (81%) 20 (19%) ,0.0001
heR2 over-expression (145 cases) 102 (70%) 43 (30%) 0.0786
Positive egFR expression (221 cases) 142 (64%) 79 (56%) 0.8293
high Ki-67 expression (.14%) (241 cases) 150 (62%) 91 (38%) 0.1861
Mean Ki-67 expression 26.19 33.98 0.0307
Table 6. Clinical-pathological features for AR expression in eR+ tumors (597 cases).
AR+ (503) AR- (94) P value
Age (mean years) 51.08 51.15 0.8394
Tumor size (mean cm) 2.06 2.17 0.6322
Positive nodal metastasis (253 cases) 217 (86%) 36 (14%) 0.4267
Positive PR expression (485 cases) 415 (86%) 70 (14%) 0.0832
heR2 over-expression (182 cases) 154 (85%) 28 (15%) 0.9035
Positive egFR expression (303 cases) 249 (82%) 54 (18%) 0.1777
high Ki-67 expression (.14%) (283 cases) 233 (82%) 50 (18%) 0.2605
Mean Ki-67 expression level 20.04 22.73 0.3825
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Table 8. The definitions for each molecular subtype.
subtype eR pR Ki67 HeR2 eGFR # of cases
Luminal A (eR+ and/or pR+, Ki67 , 14%, HeR2-) 262 cases (27%)
Luminal A + + - - + 90
Luminal A + + - - - 106
Luminal A + - - - + 17
Luminal A + - - - - 12
Luminal A - + - - + 17
Luminal A - + - - - 20
Luminal B (eR+ and/or pR+, Ki67 . 14%, HeR2-) 233 cases (24%)
Luminal B + + + - + 73
Luminal B + + + - - 80
Luminal B + - + - + 19
Luminal B + - + - - 18
Luminal B - + + - + 21
Luminal B - + + - - 22
Luminal HeR2 (eR+ and/or pR+, HeR2+) 208 cases (21%)
Luminal heR2 + + + + + 40
Luminal heR2 + + + + - 27
Luminal heR2 + + - + + 39
Luminal heR2 + + - + - 30
Luminal heR2 + - + + + 15
Luminal heR2 + - + + - 11
Luminal heR2 + - - + + 10
Lzuminal heR2 + - - + - 10
Luminal heR2 - + + + + 7
Luminal heR2 - + + + - 8
Luminal heR2 - + - + + 5
Luminal heR2 - + - + - 6
HeR2 Over-expression (eR-, pR-, HeR2+) 119 cases (12%)
heR2 - - + + + 49
heR2 - - + + - 28
heR2 - - - + + 22
heR2 - - - + - 20
Triple negative (Tn), eGFR+ (eR-, pR-, HeR2-) 100 cases (10%)
Tn, egFR+ - - + - + 73
Tn, egFR+ - - - - + 27
Triple negative (Tn), eGFR- (eR-, pR-, HeR2-) 58 cases (6%)
Triple negative - - + - - 33
Triple negative - - - - - 25
Table 9. AR expression in different molecular subtypes.
Molecular subtypes Total # AR+ %
Luminal A (eR+ and/or PR+, Ki67 , 14%, heR2-) 262 235 90%
Luminal B (eR+ and/or PR+, Ki67 . 14%, heR2-) 233 186 80%
Luminal heR2 (eR+ and/or PR+, heR2+) 208 178 86%
heR2 over-expression (eR-, PR-, heR2+) 119 78 66%
Triple negative (Tn), egFR+ (eR-, PR-, heR2-) 100 52 52%
Triple negative (Tn), egFR- (eR-, PR-, heR2-) 58 32 55%
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they  block  the  in  vivo  conversion  of  androgen  to 
estrogen.39,40 For ER+ tumors, androgen can stimu-
late cell growth;41,42 thus, the therapy should inhibit 
both ER and AR. Further studies on the role of AR 
in both ER+ and ER- breast cancers are warranted in 
order to better understand how this receptor might be 
exploited as a potential target for therapy.
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